Cargando…

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy

BACKGROUND: Immune checkpoint inhibition (ICI) has changed the melanoma treatment spectrum. Few studies have examined the characteristics and long-term outcomes of patients achieving complete response (CR) under ICI. MATERIALS AND METHODS: We evaluated patients with unresectable stage IV melanoma tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatziioannou, Eftychia, Leiter, Ulrike, Thomas, Ioannis, Keim, Ulrike, Seeber, Olivia, Meiwes, Andreas, Boessenecker, Isabell, Gonzalez, Stephanie Sanchez, Torres, Francisco Merraz, Niessner, Heike, Sinnberg, Tobias, Forschner, Andrea, Flatz, Lukas, Amaral, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195722/ https://www.ncbi.nlm.nih.gov/pubmed/37142875 http://dx.doi.org/10.1007/s40257-023-00775-7

Ejemplares similares

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
por: Amaral, Teresa, et al.
Publicado: (2020)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
por: Serna-Higuita, Lina María, et al.
Publicado: (2021)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Schmitt, Marisa, et al.
Publicado: (2021)

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
por: Fröhlich, Lisa Marie, et al.
Publicado: (2023)

Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany
por: KRAMB, Felix, et al.
Publicado: (2022)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
por: Hilke, Franz J., et al.
Publicado: (2020)

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
por: Reiter, Selina, et al.
Publicado: (2023)

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
por: Meckbach, Diana, et al.
Publicado: (2014)

High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma
por: Burkard, Markus, et al.
Publicado: (2023)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
por: Meraz-Torres, Francisco, et al.
Publicado: (2020)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
por: Sinnberg, Tobias, et al.
Publicado: (2018)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Vitamin C Deficiency in Blood Samples of COVID-19 Patients
por: Sinnberg, Tobias, et al.
Publicado: (2022)

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
por: Pflugfelder, Annette, et al.
Publicado: (2011)

The need for psycho-oncological support for melanoma patients: Central role of patients’ self-evaluation
por: Mayer, Simone, et al.
Publicado: (2017)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
por: Weide, Benjamin, et al.
Publicado: (2013)

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
por: Weide, Benjamin, et al.
Publicado: (2013)

Ex Vivo Evaluation of the Sepsis Triple Therapy High-Dose Vitamin C in Combination with Vitamin B1 and Hydrocortisone in a Human Peripheral Blood Mononuclear Cells (PBMCs) Model
por: Lauer, Annie, et al.
Publicado: (2021)

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion
por: Kosnopfel, Corinna, et al.
Publicado: (2020)

Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2014)

Great Achievements under Suffering: IV. The Blind Observer
Publicado: (1893)

Intimal aortic sarcoma mimicking ruptured thoracoabdominal type IV aneurysm. a rare case report and review of the literature
por: Dedeilias, Panagiotis, et al.
Publicado: (2011)

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
por: Wagner, Nikolaus B, et al.
Publicado: (2021)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo
por: Niessner, Heike, et al.
Publicado: (2022)

A Reevaluation of the Morphology, Paleoecology, and Phylogenetic Relationships of the Enigmatic Walrus Pelagiarctos
por: Boessenecker, Robert W., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_isq0v4uif2l3eq5f48qn27dicv